Advances in therapeutic strategies for the treatment of pruritus

Stull, Carolyn; Lavery, Michael Joseph; Yosipovitch, Gil

doi:10.1517/14656566.2016.1127355

Cited by 30 publications

(25 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,29,30 Many of the currently available therapies used for chronic pruritus have limited efficacy, and some have significant side effects. 1,31 Therefore, there is a significant unmet need for a safe, effective treatment for chronic pruritus.…”

Section: Discussionmentioning

confidence: 99%

Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial

Yosipovitch

Ständer

Kerby

et al. 2018

Journal of the American Academy of Dermatology

Self Cite

101

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial

Yosipovitch

Ständer

Kerby

et al. 2018

Journal of the American Academy of Dermatology

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…There is currently no approved causal therapy for all types of CP. However, it has been shown that neuronal hypersensitivity plays an important role in many forms of CP, and interaction with neuronal mechanisms is seen as a potential new therapeutic approach . Currently, various topical and systemic measures in CP are available as symptomatic therapy options.…”

Section: Discussionmentioning

confidence: 99%

Pruritus in patients with chronic leg ulcers: A frequent and often neglected problem

Jockenhöfer

Zaremba

Wehrmann³

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

There is a paucity of studies regarding pruritus in patients with chronic leg ulcers. Data were collected using newly developed questionnaires for patients and physicians to evaluate pruritus in individuals with chronic leg ulcers. The results show that a total of 50 patients with chronic leg ulcers were included in this prospective study. Frequent pruritus was observed in 32.0% of the participants, while 36.0% reported occasional pruritus. The average pruritus intensity was 3.5 points (0‐10 numeric rating scale [NRS]) and was found to increase with age. Patients experiencing pruritus achieved a higher Wound‐quality of life (QoL) score (32.1) as that of patients without pruritus (25.8). Additional dermatological findings around the wounds included xerosis (26.0%), eczema (4.0%), and excoriations (2.0%). Pruritus was reported by all subjects with eczema and 84.6% of those with xerosis. The pruritus lasted significantly longer in women (average 98.4 months) vs men (average 37.5 months). Interestingly, men reported more intense pruritus than women (4.4 vs 2.8). Females reported more frequent use of skin care products than males. In conclusion, the current data show that two‐thirds of patients with chronic leg ulcers suffer from moderate intense pruritus. Therefore, pruritus is a frequent and often neglected problem that should be regularly evaluated in all patients with chronic leg ulcers and considered in future therapy concepts.

show abstract

“…Some of these drugs have failed to show sufficient efficacy for further development, others showed more promising results and are in later stage trials. Excellent reviews highlight the anti‐pruritic therapies that have been in development in recent years, currently ongoing clinical trials are listed in Table . Among the ongoing trials, there are three classes of drugs that are currently in phase 3 trials: a monoclonal anti‐IgE antibody (Ligelizumab for the treatment of chronic spontaneous urticaria), opioid receptor blockers (difelikefalin and nalbuphine for the treatment of uraemic pruritus and prurigo respectively) and neurokinin 1‐receptor antagonists (tradipitant for the treatment of atopic dermatitis, and serlopitant for the treatment of prurigo and other pruritic diseases).…”

Section: Targets That Are Currently Explored In Clinical Trialsmentioning

confidence: 99%

Treatments for chronic pruritus outside of the box

Metz

2019

Experimental Dermatology

View full text Add to dashboard Cite

Patients with chronic pruritus are in desperate need of novel treatment options, as current therapeutic possibilities are often not effective, have a poor level of evidence and are mostly off‐label. In recent years, much effort has been put into the identification of potential targets for the treatment of chronic pruritus. More importantly, a number of promising new drugs that are aimed at treating pruritus in different conditions are currently in advanced stages of clinical trials. Here, current pharmacological developments leading to potential new drugs for the treatment of chronic pruritus within various conditions are summarized. Hopefully, these new approaches will result in effective and safe therapies for our patients with chronic pruritus associated with dermatological or non‐dermatological diseases in the near future.

show abstract

Advances in therapeutic strategies for the treatment of pruritus

Cited by 30 publications

References 115 publications

Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial

Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial

Pruritus in patients with chronic leg ulcers: A frequent and often neglected problem

Treatments for chronic pruritus outside of the box

Contact Info

Product

Resources

About